Evidence map›Paper›PMID 42901716›Full record

ArticleLupus science & medicine2026

Fatigue outcomes with anifrolumab in low-disease-activity SLE: DNA damage in plasmacytoid dendritic cells as a candidate biomarker for responders.

Eitaro Yoshida, Taiga Kuga, Yusuke Yanagimoto, Emi Nakanishi, Ayako Makiyama, Goh Murayama, Kentaro Minowa, Makio Kusaoi, Ken Yamaji, Naoto Tamura

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eitaro YoshidaDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
Taiga KugaDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan t-kuga@juntendo.ac.jp.ORCID http://orcid.org/0009-0009-4959-7892
Yusuke YanagimotoDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
Emi NakanishiDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
Ayako MakiyamaDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
Goh MurayamaDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
Kentaro MinowaDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0370-2297
Makio KusaoiDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0064-4765
Ken YamajiDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.
Naoto TamuraDepartment of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Autoimmune DiseasesFatigueHealth-Related Quality Of LifeInterferon Type ILupus Erythematosus, Systemic

Identifiers

PMID42901716
PMCPMC13684201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.